
DexCom, Inc. – NASDAQ:DXCM
DexCom stock price today
DexCom stock price monthly change
DexCom stock price quarterly change
DexCom stock price yearly change
DexCom key metrics
Market Cap | 30.53B |
Enterprise value | 47.01B |
P/E | 140.29 |
EV/Sales | 16.15 |
EV/EBITDA | 83.16 |
Price/Sales | 15.39 |
Price/Book | 21.01 |
PEG ratio | 1.16 |
EPS | 1.66 |
Revenue | 3.80B |
EBITDA | 867.3M |
Income | 639.3M |
Revenue Q/Q | 24.20% |
Revenue Y/Y | 25.78% |
Profit margin | 11.73% |
Oper. margin | 13.44% |
Gross margin | 64.72% |
EBIT margin | 13.44% |
EBITDA margin | 22.81% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeDexCom stock price history
DexCom stock forecast
DexCom financial statements
Jun 2023 | 871.3M | 115.9M | 13.3% |
---|---|---|---|
Sep 2023 | 975M | 120.7M | 12.38% |
Dec 2023 | 1.03B | 256.3M | 24.78% |
Mar 2024 | 921M | 146.4M | 15.9% |
Sep 2025 | 1.35B | 266.84M | 19.7% |
---|---|---|---|
Oct 2025 | 1.35B | 270.70M | 19.95% |
Dec 2025 | 1.43B | 293.35M | 20.39% |
Mar 2026 | 1.32B | 229.26M | 17.26% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 6820700000 | 4.72B | 69.21% |
---|---|---|---|
Sep 2023 | 6596200000 | 4.32B | 65.62% |
Dec 2023 | 6264500000 | 4.19B | 66.98% |
Mar 2024 | 6482200000 | 4.23B | 65.34% |
Jun 2023 | 190.3M | -555.9M | 939.5M |
---|---|---|---|
Sep 2023 | 269.2M | -179.5M | -637.4M |
Dec 2023 | 133.6M | 414.9M | -631.9M |
Mar 2024 | 209.2M | 74.8M | 4.7M |
DexCom alternative data
Aug 2023 | 74 |
---|---|
Sep 2023 | 70 |
Oct 2023 | 85 |
Nov 2023 | 79 |
Dec 2023 | 92 |
Jan 2024 | 84 |
Feb 2024 | 83 |
Mar 2024 | 84 |
Apr 2024 | 89 |
May 2024 | 88 |
Jun 2024 | 87 |
Aug 2023 | 65 |
---|---|
Sep 2023 | 60 |
Oct 2023 | 54 |
Nov 2023 | 41 |
Dec 2023 | 55 |
Jan 2024 | 49 |
Feb 2024 | 47 |
Mar 2024 | 48 |
Apr 2024 | 39 |
May 2024 | 34 |
Jun 2024 | 44 |
Aug 2023 | 70 |
---|---|
Sep 2023 | 66 |
Oct 2023 | 83 |
Nov 2023 | 86 |
Dec 2023 | 68 |
Jan 2024 | 82 |
Feb 2024 | 76 |
Mar 2024 | 62 |
Apr 2024 | 74 |
May 2024 | 74 |
Jun 2024 | 53 |
Aug 2023 | 73 |
---|---|
Sep 2023 | 69 |
Oct 2023 | 93 |
Nov 2023 | 89 |
Dec 2023 | 91 |
Jan 2024 | 100 |
Feb 2024 | 95 |
Mar 2024 | 88 |
Apr 2024 | 101 |
May 2024 | 114 |
Jun 2024 | 88 |
Apr 2024 | 177 |
---|---|
May 2024 | 179 |
Jun 2024 | 191 |
Nov 2023 | 64 |
---|---|
Dec 2023 | 61 |
Jan 2024 | 53 |
Feb 2024 | 54 |
Mar 2024 | 49 |
Apr 2024 | 45 |
May 2024 | 50 |
Jun 2024 | 55 |
DexCom Social Media Accounts
May 2025 | 178596 |
---|---|
Jul 2025 | 180078 |
Aug 2025 | 180908 |
Aug 2023 | 197434 |
---|---|
Sep 2023 | 198645 |
Areas of Focus
19 Feb 2023 | 72 |
---|---|
26 Feb 2023 | 72 |
5 Mar 2023 | 73 |
12 Mar 2023 | 72 |
19 Mar 2023 | 78 |
26 Mar 2023 | 74 |
2 Apr 2023 | 76 |
9 Apr 2023 | 75 |
16 Apr 2023 | 74 |
23 Apr 2023 | 77 |
30 Apr 2023 | 74 |
7 May 2023 | 76 |
14 May 2023 | 74 |
21 May 2023 | 72 |
28 May 2023 | 86 |
4 Jun 2023 | 82 |
11 Jun 2023 | 74 |
18 Jun 2023 | 76 |
25 Jun 2023 | 70 |
2 Jul 2023 | 69 |
Dexcom
4 Aug 2024 | 52 |
---|---|
11 Aug 2024 | 53 |
18 Aug 2024 | 48 |
25 Aug 2024 | 48 |
1 Sep 2024 | 47 |
8 Sep 2024 | 40 |
15 Sep 2024 | 40 |
22 Sep 2024 | 41 |
29 Sep 2024 | 39 |
6 Oct 2024 | 39 |
13 Oct 2024 | 41 |
20 Oct 2024 | 42 |
27 Oct 2024 | 44 |
3 Nov 2024 | 42 |
10 Nov 2024 | 45 |
17 Nov 2024 | 42 |
24 Nov 2024 | 40 |
1 Dec 2024 | 43 |
8 Dec 2024 | 42 |
15 Dec 2024 | 41 |
Dexcom Products
26 Feb 2023 | 0 |
---|---|
5 Mar 2023 | 0 |
12 Mar 2023 | 0 |
19 Mar 2023 | 0 |
26 Mar 2023 | 0 |
2 Apr 2023 | 0 |
9 Apr 2023 | 0 |
16 Apr 2023 | 0 |
23 Apr 2023 | 0 |
30 Apr 2023 | 0 |
7 May 2023 | 0 |
14 May 2023 | 0 |
21 May 2023 | 0 |
28 May 2023 | 0 |
4 Jun 2023 | 0 |
11 Jun 2023 | 0 |
18 Jun 2023 | 0 |
25 Jun 2023 | 0 |
2 Jul 2023 | 0 |
9 Jul 2023 | 0 |
Diabetes Management
19 Feb 2023 | 59 |
---|---|
26 Feb 2023 | 63 |
5 Mar 2023 | 54 |
12 Mar 2023 | 63 |
19 Mar 2023 | 82 |
26 Mar 2023 | 69 |
2 Apr 2023 | 75 |
9 Apr 2023 | 67 |
16 Apr 2023 | 76 |
23 Apr 2023 | 77 |
30 Apr 2023 | 76 |
7 May 2023 | 63 |
14 May 2023 | 66 |
21 May 2023 | 65 |
28 May 2023 | 67 |
4 Jun 2023 | 72 |
11 Jun 2023 | 67 |
18 Jun 2023 | 63 |
25 Jun 2023 | 65 |
2 Jul 2023 | 61 |
Numbers represent search interest relative to the highest point on the chart for the given region and time.
A value of 100 is the peak popularity for the term.
A value of 50 means that the term is half as popular.
A score of 0 means there was not enough data for this term.
Aug 2023 | 263 |
---|---|
Sep 2023 | 274 |
Oct 2023 | 375 |
Nov 2023 | 262 |
Dec 2023 | 267 |
Jan 2024 | 432 |
Feb 2024 | 301 |
Apr 2024 | 341 |
May 2024 | 300 |
Jun 2024 | 347 |
Jul 2024 | 298 |
Aug 2023 | 7,500 |
---|---|
Sep 2023 | 7,500 |
Oct 2023 | 7,500 |
Nov 2023 | 7,500 |
Dec 2023 | 7,500 |
Jan 2024 | 7,500 |
Feb 2024 | 7,500 |
Mar 2024 | 9,500 |
Apr 2024 | 9,500 |
May 2024 | 9,500 |
Jun 2024 | 9,500 |
Jul 2024 | 9,500 |
DexCom other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 48507 |
Feb 2024 | 0 | 3363 |
Mar 2024 | 0 | 158865 |
Apr 2024 | 0 | 52252 |
May 2024 | 0 | 3075 |
Jun 2024 | 0 | 9576 |
Jul 2024 | 0 | 652 |
Aug 2024 | 0 | 686 |
Sep 2024 | 0 | 2918 |
Nov 2024 | 0 | 7759 |
Dec 2024 | 0 | 2912 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Sale | STERN SADIE officer: EVP, Chief HR Officer | Common Stock | 424 | $76.87 | $32,593 | ||
Sale | SYLVAIN JEREME M officer: EVP, Chief Financal Of.. | Common Stock | 744 | $76.87 | $57,191 | ||
Sale | LEACH JACOB STEVEN officer: EVP, Chi.. | Common Stock | 744 | $76.87 | $57,191 | ||
Sale | HELLER BRIDGETTE P director | Common Stock | 1,000 | $76.87 | $76,870 | ||
Sale | STERN SADIE officer: EVP, Chief HR Officer | Common Stock | 4,259 | $74.73 | $318,275 | ||
Sale | SYLVAIN JEREME M officer: EVP, Chief Financal Of.. | Common Stock | 3,500 | $75.51 | $264,285 | ||
Sale | HELLER BRIDGETTE P director | Common Stock | 1,000 | $70 | $70,000 | ||
Sale | STERN SADIE officer: EVP, Chief HR Officer | Common Stock | 426 | $69.15 | $29,458 | ||
Sale | SYLVAIN JEREME M officer: EVP, Chief Financal Of.. | Common Stock | 746 | $69.15 | $51,586 | ||
Sale | LEACH JACOB STEVEN officer: EVP, Chi.. | Common Stock | 746 | $69.15 | $51,586 |
Patent |
---|
Grant Filling date: 5 Jun 2018 Issue date: 6 Sep 2022 |
Grant Utility: Performance reports associated with continuous sensor data from multiple analysis time periods Filling date: 1 Feb 2017 Issue date: 6 Sep 2022 |
Application Filling date: 18 May 2022 Issue date: 1 Sep 2022 |
Application Filling date: 13 May 2022 Issue date: 1 Sep 2022 |
Grant Filling date: 30 Jun 2020 Issue date: 30 Aug 2022 |
Grant Filling date: 21 Nov 2018 Issue date: 30 Aug 2022 |
Application Filling date: 23 Feb 2022 Issue date: 25 Aug 2022 |
Application Filling date: 4 Oct 2021 Issue date: 25 Aug 2022 |
Grant Filling date: 27 Aug 2021 Issue date: 16 Aug 2022 |
Grant Filling date: 30 May 2019 Issue date: 16 Aug 2022 |
Quarter | Transcript |
---|---|
Q1 2024 25 Apr 2024 | Q1 2024 Earnings Call Transcript |
Q4 2023 8 Feb 2024 | Q4 2023 Earnings Call Transcript |
Q3 2023 26 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
DexCom's ADA Conference Takeaways: Stelo, CGM Tailwinds Still Intact
Showcasing Seeking Alpha's May 2024 New Analysts
Dexcom: Positive Catalysts Ahead To Support Growth
DexCom: Attractive Discount After Strong Earnings Results
DexCom Is Pricey For A Reason - Its Growth Story Reflects That
International Companies Drive Diabesity Innovation
indie Semiconductor: 50 Top Growth Stocks, These 3 Worth Considering
DexCom: Stelo Stellar Outlook
Esperion Is Sitting On A Potential Blockbuster Drug
-
What's the price of DexCom stock today?
One share of DexCom stock can currently be purchased for approximately $81.
-
When is DexCom's next earnings date?
Unfortunately, DexCom's (DXCM) next earnings date is currently unknown.
-
Does DexCom pay dividends?
No, DexCom does not pay dividends.
-
How much money does DexCom make?
DexCom has a market capitalization of 30.53B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 24.49% to 3.62B US dollars.
-
What is DexCom's stock symbol?
DexCom, Inc. is traded on the NASDAQ under the ticker symbol "DXCM".
-
What is DexCom's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of DexCom?
Shares of DexCom can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are DexCom's key executives?
DexCom's management team includes the following people:
- Mr. Kevin Ronald Sayer Executive Chairman, Chief Executive Officer & Pres(age: 67, pay: $2,630,000)
- Mr. Jacob Steven Leach Executive Vice President & Chief Technology Officer(age: 47, pay: $1,000,000)
-
How many employees does DexCom have?
As Jul 2024, DexCom employs 9,500 workers.
-
When DexCom went public?
DexCom, Inc. is publicly traded company for more then 20 years since IPO on 14 Apr 2005.
-
What is DexCom's official website?
The official website for DexCom is dexcom.com.
-
Where are DexCom's headquarters?
DexCom is headquartered at 6340 Sequence Drive, San Diego, CA.
-
How can i contact DexCom?
DexCom's mailing address is 6340 Sequence Drive, San Diego, CA and company can be reached via phone at 858 200 0200.
DexCom company profile:

DexCom, Inc.
dexcom.comNASDAQ
9,500
Medical - Devices
Healthcare
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
San Diego, CA 92121
CIK: 0001093557
ISIN: US2521311074
CUSIP: 252131107